Navigation Links
Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)
Date:5/23/2013

ATLANTA, May 23, 2013 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease treatments, announced today that it will present new results on its antiviral program to 'prevent' PML at an industry conference sponsored by the PML Consortium (composed of Pfizer, Bristol-Meyers Squibb, Roche and Biogen Idec).  JC polyomavirus (JCV) is the causative agent of Progressive Multifocal Leukoencephalopathy (PML). IkT-001Pro, a host-directed tyrosine kinase inhibitor in an extended release formulation, can clear JC polyomavirus (JCV) infection in at least some patients and is active against the form of the virus that infects the majority of human beings. The Company will present preliminary outcomes of its proposed treatment to 'prevent' PML.  This oral medication, taken once or twice daily, is compatible with many different monoclonal antibody-based therapies and may offer a general solution to JCV infection as a companion therapeutic.

"JCV infection progresses to PML only in patients with chronic or drug-induced immune suppression. The ability to clear JCV infection in at least some patients is encouraging.  Further clinical evaluation confirming preliminary results is underway in several patient groups," said Milton H. Werner Ph.D., Chief Executive Officer and President of Inhibikase Therapeutics. 

About Inhibikase Therapeutics

Founded in 2008, Inhibikase Therapeutics is a private biopharmaceutical company developing novel, small-molecule compounds to treat bacterial, viral, fungal and parasitic diseases through a common mechanism of action, often involving a single drug.  Its pipeline of validated targets treat diseases therapeutically and prophylactically.  By inhibiting human pathways used by multiple bacteria and viruses for reproduction in the patient, the Company's compounds resolve infection with a lower likelihood of stimulating resistance. Inhibikase Therapeutics is also developing a broad-spectrum antiviral specific for enveloped viruses, opening new avenues for vaccine development and biodefense. For more information, please visit the Company's website at www.inhibikase.com.

For Further Information Contact:

Milton H. Werner , PhD
President & CEO
Inhibikase Therapeutics, Inc.
(917) 494-0831 (m)
mhwerner@inhibikase.com


'/>"/>
SOURCE Inhibikase Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
2. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
3. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
4. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
5. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
6. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
7. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
9. Novelos Therapeutics Provides Product Pipeline Update
10. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
11. Mast Therapeutics Reports First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... , June 14, 2017 The Bio Supply ... City of Fremont and the Biomedical ... bio-pharma industry in California by ... executive networking, and fostering workforce development. The primary focus ... growth of start-ups, as well as small and mid-sized ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
(Date:6/8/2017)... , June 8, 2017  Less than a ... hit more than 200,000 companies, including hospital networks, in ... heralded as one of the largest online extortion attempts ... the healthcare market, it is imperative that providers understand ... their data from this — and many other very ...
Breaking Medicine Technology:
(Date:6/28/2017)... Philadelphia, PA (PRWEB) , ... June 28, 2017 ... ... will host a one-day corporate governance program for mid-market executives as a kick-off ... will be held Sunday, Sept. 24, 2017 on the University of Pennsylvania campus, ...
(Date:6/28/2017)... Vancouver, British Columbia (PRWEB) , ... June 28, ... ... (OTCQB: CNZCF) (FSE: ZEON) is pleased to announce that a two year study ... using the Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers ... to communities in northern Virginia and DC, is announcing a cooperative charity event ... with Alzheimer’s and other disorders that lead to memory impairment. , The Insight ...
(Date:6/27/2017)... Rolling Meadows, IL (PRWEB) , ... June 27, ... ... they are considering a cosmetic treatment, according to survey data released today by ... Consumer Survey on Cosmetic Dermatologic Procedures indicates the percentage of consumers considering ...
(Date:6/27/2017)... ... 2017 , ... Salucro, the cloud-based payment platform that has ... and provider groups, has announced that it will now offer Parasail’s payment plans ... San Francisco health-finance startup that has launched a series of tech-based products that ...
Breaking Medicine News(10 mins):